Cabaletta Bio, Inc. carries a market capitalization of 250.93M, placing it among publicly traded companies globally. Its enterprise value stands at 322.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 250.93M |
| Enterprise Value | 322.24M |
Cabaletta Bio, Inc. currently has 167.73M shares outstanding.
| Shares Outstanding | 167.73M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 2.48 |
| P/TBV Ratio | 2.48 |
| P/FCF Ratio | -2.47 |
| P/OCF Ratio | -2.46 |
Cabaletta Bio, Inc. maintains a current ratio of 5.79, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.21, indicating elevated leverage, while an interest coverage ratio of -80.33 demonstrates limited ability to service its debt obligations.
| Current Ratio | 5.79 |
| Quick Ratio | 5.64 |
| Debt / Equity | 12.21 |
| Debt / EBITDA | -0.14 |
| Interest Coverage | -80.33 |
| Return on Equity (ROE) | -93.20 |
| Return on Assets (ROA) | -75.36 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Cabaletta Bio, Inc.'s stock has declined approximately -47.51773% over the past 52 weeks. The 50-day moving average sits at 2.55, while the 200-day moving average is 2.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | -47.51773% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 2.89 |
| Average Volume (20 Days) | N/A |
EBITDA reached -184.11M, while operating income came in at -185.52M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -185.52M |
| Pretax Income | -181.32M |
| Net Income | -181.32M |
| EBITDA | -184.11M |
| EBIT | -185.52M |
| Earnings Per Share (EPS) | -1.49 |
Cabaletta Bio, Inc. holds 225.10M in cash and equivalents against 25.71M in total debt, resulting in a net debt position of -225.10M. Total book value stands at 210.59M, with working capital of 191.12M providing operational flexibility.
| Cash & Cash Equivalents | 225.10M |
| Total Debt | 25.71M |
| Net Debt | -225.10M |
| Equity (Book Value) | 210.59M |
| Book Value Per Share | 1.26 |
| Working Capital | 191.12M |
Cabaletta Bio, Inc. produced -153.93M in operating cash flow over the past twelve months. After subtracting -283,000.00 in capital expenditures, free cash flow totaled -154.21M - equivalent to -1.27 per share.
| Operating Cash Flow | -153.93M |
| Capital Expenditures | -283,000.00 |
| Free Cash Flow | -154.21M |
| FCF Per Share | -1.27 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -35.04 |
| FCF Yield | -40.56 |
Cabaletta Bio, Inc. posts an Altman Z-Score of 1.96, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.96 |